Tattoos May Be a Risk Factor for Lymphoma Swedish study suggests a 21% higher risk for lymphoma in those with tattoos May 28, 2024
Five Doctor 51˶ With the Most Burnout in 2024 Emergency medicine and ob/gyn top the list May 24, 2024
Doubt Cast on MGUS-Autoimmune Disease Link Population-based study fails to confirm earlier findings May 20, 2024
What to Know About the U.K.'s Tainted Blood Scandal Tens of thousands contracted HIV or hepatitis from transfusions during the 1970s and 1980s May 20, 2024
Mortality in U.S. Youth; Gene Therapy for Sickle Cell Disease Also in TTHealthWatch: updated breast cancer screening guidelines May 11, 2024 podcast
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise News, features, and commentary about cancer-related issues May 10, 2024
Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show Study finds survival is comparable to that seen in younger patients in VIALE-A trial May 09, 2024
Impact of Recombinant Replacement Therapy Detailed in Genetic Clotting Disorder Trial that led to FDA approval shows a big difference in replacement levels versus usual care May 01, 2024
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management Genetics already informs prognosis, may help guide therapy development beyond JAK2 inhibition May 01, 2024
Myelofibrosis: A Rare Malignancy Attracting More and More Attention Increased interest follows mutation discoveries, development of targeted therapies May 01, 2024
New E. Coli Outbreak; How ECMO Redefines Death; A Step Closer to Universal Blood Health news and commentary gathered by 51˶ staff May 01, 2024
FDA Approves First Drug for WHIM Syndrome CXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes to reduce infections Apr 29, 2024
Clue to Aspirin, Colon Cancer Link; New Lutathera Approval; AI & Electronic Records News, features, and commentary about cancer-related issues Apr 26, 2024
FDA OKs Second Gene Therapy for Hemophilia B One dose of fidanacogene elaparvovec proved noninferior to standard prophylactic factor IX Apr 26, 2024
Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCT ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease Apr 26, 2024
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL Undetectable disease rate over 90%, ctDNA also promising for earlier detection of recurrence Apr 24, 2024
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers "All-in-one" approach appears safe, effective, in patients with relapsed/refractory disease Apr 24, 2024
Immunotherapy During Pregnancy Just as Safe as Other Cancer Drugs However, use should be avoided "if possible" due to risk of rare immune-related adverse events Apr 17, 2024
FDA Approves Earlier Use of CAR-T Products for Myeloma Carvykti and Abecma move to second- and third-line, respectively Apr 08, 2024
High Response Rate in R/R Multiple Myeloma With Bispecific Antibody ORR of 71% that deepened over time and favorable safety profile with linvoseltamab Apr 08, 2024
Factor D Inhibitor Wins Approval for PNH With Extravascular Hemolysis Danicopan significantly improved hemoglobin at 12 weeks when added to a C5 inhibitor Apr 04, 2024
FDA OKs Injectable Antibiotic for Three Different Uses Ceftobiprole was at least comparable to currently used medications in studies Apr 03, 2024
Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendations News, features, and commentary about cancer-related issues Mar 29, 2024
PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma The combination induced responses in all 34 patients with advanced extranodal NK/T-cell lymphoma Mar 28, 2024
Breastfeeding Tied to Reduced Childhood Leukemia Risk Lower pediatric ALL risk in Danish study when mothers exclusively breastfed for 3 months or more Mar 27, 2024
New Monoclonal Authorized to Prevent COVID in Immunocompromised People No such option has been available since FDA revoked the authorization of Evusheld last year Mar 22, 2024
FDA Approves New Frontline Regimen for Aggressive ALL Ponatinib lands indication in combination with chemo for Philadelphia chromosome-positive cases Mar 22, 2024
Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer News, features, and commentary about cancer-related issues Mar 22, 2024
Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors Treated With Doxorubicin Dose-dependent increase regardless of age at treatment or chest radiotherapy Mar 19, 2024
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma Cilta-cel, ide-cel win support despite concerns about early mortality risk Mar 16, 2024
FDA Approves First CAR-T for Chronic Lymphocytic Leukemia Lisocabtagene maraleucel (Breyanzi) nabs new indication for relapsed or refractory CLL/SLL Mar 15, 2024
FDA Panel Endorses Imetelstat for MDS-Related Anemia By 12-2 vote, members find improvement in transfusion independence outweighs risk Mar 14, 2024
Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting Mar 14, 2024
Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity' News, features, and commentary about cancer-related issues Mar 14, 2024
FDA Staff Cast Doubt on Novel Drug for MDS-Related Anemia Agency asking its advisors if benefits outweigh risks for patients who fail on standard treatment Mar 12, 2024
Sickle Cell Pain Hospitalizations Rose After CDC's Opioid Recs Agency's 2016 guidance may have contributed to reduced access to opioids, and more pain Mar 11, 2024
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu News, features, and commentary about cancer-related issues Mar 07, 2024
Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients Talk of potential cure for some patients with brentuximab plus dacarbazine or nivolumab Mar 06, 2024
IVF Helps Patients Trying to Build Families. An Alabama Court Put That in Doubt "Every month that you're not pregnant feels like grief" Mar 05, 2024
All-Oral AML Regimen Shows Promise for Older, Unfit Patients Response rate of 64% in newly diagnosed patients, 46% in those with refractory/relapsed disease Mar 05, 2024
